Bonus Biogroup

Bonus BioGroup is a clinical-stage Israeli biotechnology company focusing on the R&D of tissue-engineered and cell therapy products. Founded in 2008 by CEO Dr. Shai Meretzki, a prominent figure in Israel's biotech sector, Bonus BioGroup is at the forefront of developing innovative treatment solutions. The company's flagship product, BonoFill, is the world's first viable tissue-engineered bone graft, utilizing mesenchymal cells isolated from the patient's adipose tissue. This groundbreaking approach has already led to successful bone regeneration in numerous patients with severe bone defects. In response to the coronavirus outbreak, Bonus BioGroup has also initiated the development of MesenCure, a treatment based on mesenchymal cells intended to address life-threatening pneumonia and cytokine storm in severe COVID-19 cases. As a result of promising clinical outcomes and established manufacturing capabilities, Bonus BioGroup is dedicated to advancing regenerative medicine and cementing its position as a global leader in the field, with a focus on impactful and life-saving treatments.